Literature DB >> 8026530

Expression of a transgenic class II Ab gene confers susceptibility to collagen-induced arthritis.

U Brunsberg1, K Gustafsson, L Jansson, E Michaëlsson, L Ahrlund-Richter, S Pettersson, R Mattsson, R Holmdahl.   

Abstract

The major histocompatibility complex (MHC) class II region is assumed to influence autoimmune diseases such as rheumatoid arthritis. In the mouse, the H-2q haplotype is associated with susceptibility to collagen-induced arthritis, while the H-2p haplotype is not. The class II A molecules of these haplotypes differ by only four amino acids in the first domain of the beta chain. To test if this difference accounts for the MHC influence on susceptibility to collagen-induced arthritis, H-2p mice were made transgenic with an Abp gene altered to resemble the Abq gene. The transgenic A beta chain hybridized with the A alpha p chain and was shown to be physiologically expressed by testing antigen-presentation capacity to Aq-restricted T cell hybridomas and with FACS analyses. These transgenic mice developed an autoimmune response to type II collagen and also collagen-induced arthritis. The data unequivocally suggest the Ab gene as a major genetic susceptibility locus for autoimmune collagen-induced arthritis.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8026530     DOI: 10.1002/eji.1830240736

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  43 in total

1.  Collagen type II and a thermo-responsive polymer of N-isopropylacrylamide induce arthritis independent of Toll-like receptors: a strong influence by major histocompatibility complex class II and Ncf1 genes.

Authors:  Akhilesh Kumar Shakya; Ashok Kumar; Dorota Klaczkowska; Malin Hultqvist; Kristin Hagenow; Rikard Holmdahl; Kutty Selva Nandakumar
Journal:  Am J Pathol       Date:  2011-09-18       Impact factor: 4.307

2.  T cell responses to a non-glycosylated epitope predominate in type II collagen-immunised HLA-DRB1*0101 transgenic mice.

Authors:  Alexei von Delwig; Daniel M Altmann; Fraser G Charlton; Norman McKie; John D Isaacs; Rikard Holmdahl; John H Robinson
Journal:  Ann Rheum Dis       Date:  2006-11-17       Impact factor: 19.103

Review 3.  Rodent models of arthritis: relevance for human disease.

Authors:  R O Williams
Journal:  Clin Exp Immunol       Date:  1998-12       Impact factor: 4.330

4.  A physical map of the Q region of B1O.P.

Authors:  W Litaker; A Peace-Brewer; J A Frelinger
Journal:  Mamm Genome       Date:  1996-03       Impact factor: 2.957

5.  B cell-deficient mice do not develop type II collagen-induced arthritis (CIA).

Authors:  L Svensson; J Jirholt; R Holmdahl; L Jansson
Journal:  Clin Exp Immunol       Date:  1998-03       Impact factor: 4.330

6.  Sequence analysis of MHC class II Eb cDNAs from H2r and H2p haplotypes.

Authors:  B Y Wei; H Cao; S Pan; C S David
Journal:  Immunogenetics       Date:  1996       Impact factor: 2.846

7.  The plasminogen activator/plasmin system is essential for development of the joint inflammatory phase of collagen type II-induced arthritis.

Authors:  Jinan Li; Annelii Ny; Göran Leonardsson; Kutty Selva Nandakumar; Rikard Holmdahl; Tor Ny
Journal:  Am J Pathol       Date:  2005-03       Impact factor: 4.307

8.  V beta 11+ T-lymphocyte expansion by toxic shock syndrome toxin-1 differs in mice bearing H-2q versus H-2b haplotypes.

Authors:  Y X Zhao; U Brunsberg; R Holmdahl; A Tarkowski
Journal:  Immunology       Date:  1998-05       Impact factor: 7.397

9.  Enhanced autoimmunity, arthritis, and encephalomyelitis in mice with a reduced oxidative burst due to a mutation in the Ncf1 gene.

Authors:  Malin Hultqvist; Peter Olofsson; Jens Holmberg; B Thomas Bäckström; Jesper Tordsson; Rikard Holmdahl
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-13       Impact factor: 11.205

Review 10.  The value of animal models in predicting genetic susceptibility to complex diseases such as rheumatoid arthritis.

Authors:  Emma Ahlqvist; Malin Hultqvist; Rikard Holmdahl
Journal:  Arthritis Res Ther       Date:  2009-05-19       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.